The identification and in-depth understanding of intracellular signalling pathways led to the synthesis and discovery of many agents targeting cancer cells. In this study, we investigated for the first time the effect of anticancer agent ukrain as a single agent or in combination with cisplatin, etoposide, 5-fluorouracil, quercetin and bortezomib in 4T1 breast cancer and B16F10 melanoma cells. It was found that ukrain is cytotoxic and apoptotic in 4T1 breast carcinoma and B16F10 melanoma cells when given alone. The IC50 value of ukrain in 4T1 cells was found as 40 +/- 6.8 mu M and that in B16F10 cells as 76 +/- 10 mu M. It was then found that apoptosis can be induced in 4T1 breast cancer cells in a dose-dependent manner in response to ukrai...
Abstract Objectives Our aim was to compare the cyto...
Abstract Objectives Our aim was to compare the cyto...
Abstract Objectives Our aim was to compare the cyto...
The identification and in-depth understanding of intracellular signalling pathways led to the synthe...
The identification and in-depth understanding of intracellular signalling pathways led to the synthe...
The identification and in-depth understanding of intracellular signalling pathways led to the synthe...
The identification and in-depth understanding of intracellular signalling pathways led to the synthe...
Despite the recent advances in anti-cancer therapies, breast cancer accounts for the highest percent...
WOS: 000321079300046PubMed ID: 23660746Bortezomib is a highly selective and reversible inhibitor of ...
Bortezomib is a highly selective and reversible inhibitor of the 26S proteasome. It has been approve...
Bortezomib is a highly selective and reversible inhibitor of the 26S proteasome. It has been approve...
Bortezomib is a highly selective and reversible inhibitor of the 26S proteasome. It has been approve...
Bortezomib is a highly selective and reversible inhibitor of the 26S proteasome. It has been approve...
Bortezomib is a highly selective and reversible inhibitor of the 26S proteasome. It has been approve...
Abstract Objectives Our aim was to compare the cyto...
Abstract Objectives Our aim was to compare the cyto...
Abstract Objectives Our aim was to compare the cyto...
Abstract Objectives Our aim was to compare the cyto...
The identification and in-depth understanding of intracellular signalling pathways led to the synthe...
The identification and in-depth understanding of intracellular signalling pathways led to the synthe...
The identification and in-depth understanding of intracellular signalling pathways led to the synthe...
The identification and in-depth understanding of intracellular signalling pathways led to the synthe...
Despite the recent advances in anti-cancer therapies, breast cancer accounts for the highest percent...
WOS: 000321079300046PubMed ID: 23660746Bortezomib is a highly selective and reversible inhibitor of ...
Bortezomib is a highly selective and reversible inhibitor of the 26S proteasome. It has been approve...
Bortezomib is a highly selective and reversible inhibitor of the 26S proteasome. It has been approve...
Bortezomib is a highly selective and reversible inhibitor of the 26S proteasome. It has been approve...
Bortezomib is a highly selective and reversible inhibitor of the 26S proteasome. It has been approve...
Bortezomib is a highly selective and reversible inhibitor of the 26S proteasome. It has been approve...
Abstract Objectives Our aim was to compare the cyto...
Abstract Objectives Our aim was to compare the cyto...
Abstract Objectives Our aim was to compare the cyto...
Abstract Objectives Our aim was to compare the cyto...